Idaho Falls, Idaho, June 18th, 2025. International Isotopes Inc. (OTCQB: INIS), a leading supplier of radiopharmaceuticals, nuclear medicine products, and radiochemicals, is proud to announce a new distribution agreement with TerThera, the premier producer of Terbium-161 (Tb161), a promising next-generation therapeutic radionuclide. Under this agreement, International Isotopes will distribute TerThera’s Tb-161 in the United States to selected sites.
This announcement coincides with TerThera’s recent achievement of Good Manufacturing Practice (GMP) certification, marking a significant milestone in the company’s readiness to supply high-quality radiopharmaceutical-grade Tb-161 for clinical and commercial use. The certification underscores TerThera’s commitment to meeting rigorous international quality standards and accelerating the development of novel radiotherapeutics.
“Terbium-161 holds immense potential in targeted radionuclide therapy,” said Shahe Bagerdjian, President and CEO of International Isotopes Inc. “We are excited to bring this important isotope to the U.S. market and partner with TerThera to support the growth of next-generation cancer treatments.”
Tb-161 is a beta-emitting isotope with Internal Conversion and Auger electrons, making it particularly effective for small tumor lesions and micrometastases. It has drawn strong interest from radiopharmaceutical developers as a potential alternative or complement to existing therapeutic isotopes like Lutetium-177.
With this distribution agreement, International Isotopes will support researchers, clinical trial sponsors, and commercial partners in gaining access to Tb-161 throughout the United States.
About International Isotopes Inc.
International Isotopes Inc. (INIS) manufactures and distributes a wide range of radioactive isotopes and radiochemicals for medical, research, and industrial applications. The company is a trusted partner in the nuclear medicine industry and supports innovation in diagnostic and therapeutic radiopharmaceuticals.
About TerThera
TerThera is a leading radiopharmaceutical company specializing in the commercial scale production of Terbium-161. With a focus on quality, innovation, and clinical impact, TerThera is committed to advancing targeted radionuclide therapy and enabling access to next-generation isotopes.
International Isotopes Contact:
admin@intisoid.com
intisoid.com
208.524.5300